Persistent Chest Pain Following COVID‐19 Infection – A Scoping Review
Eva Kubrova,Alejandro J. Hallo‐Carrasco,Johana Klasova,Robert D. Pagan Rosado,Christian C. Prusinski,Oleksandr Trofymenko,Justin B. Schappell,Larry J. Prokop,Clara I. Yuh,Sahil Gupta,Christine L. Hunt
DOI: https://doi.org/10.1002/pmrj.13098
2023-11-02
PM&R
Abstract:Introduction Persistent chest pain (PCP) following acute COVID‐19 infection is a commonly reported symptom with an unclear etiology, making its management challenging. This scoping review aims to address the knowledge gap surrounding the characteristics of PCP following COVID‐19, its causes, and potential treatments. Objective To assess the prevalence, causes, and potential treatments of PCP following COVID‐19 infection. Design A scoping review of 64 studies, including observational (prospective, retrospective, cross‐sectional, case series, and case‐control) and one quasi‐experimental study, from databases including Embase, PubMed/MEDLINE, Cochrane CENTRAL, Google Scholar, Cochrane Database of Systematic Reviews, and Scopus. Setting Studies on patients with PCP following mild, moderate, and severe COVID‐19 infection. Patients Studies that included patients of any age, with chest pain that persisted following acute COVID‐19 disease, irrespective of etiology or duration. Interventions Not applicable. Main Outcome Measure(s) Prevalence, causes, and potential treatments of PCP following COVID‐19 infection. Results A total of 35 studies reported PCP symptoms following COVID‐19 (0.24‐76.6%) at an average follow‐up of three months or longer, 12 studies at 1‐3 months and 17 studies at less than one month follow‐up or not specified. PCP was common following mild ‐ severe COVID‐19 infection, and etiology was mostly not reported. Fourteen studies proposed potential etiologies including endothelial dysfunction, cardiac ischemia, vasospasm, myocarditis, cardiac arrhythmia, pneumonia, pulmonary embolism, postural tachycardia syndrome (POTS), or noted cardiac MRI (cMRI) changes. Evaluation methods included common cardiopulmonary tests, as well as less common tests such as flow‐mediated dilatation (FMD), cMRI, single‐photon emission computed tomography myocardial perfusion imaging (SPECT‐MPI), and cardiopulmonary exercise testing (CPET). Only one study reported a specific treatment (sulodexide). Conclusions PCP is a prevalent symptom following COVID‐19 infection, with various proposed etiologies. Further research is needed to establish a better understanding of the causes and to develop targeted treatments for PCP following COVID‐19. This article is protected by copyright. All rights reserved.
rehabilitation,sport sciences